

British Neuro- Oncology Society Annual Meeting 2026

**Local Therapies for Brain Cancers – Patient variability/
Emerging treatments / Optimising outcomes**



**Wednesday 1st – Friday 3rd July 2026
The University of Birmingham**



NORTHWEST BIOTHERAPEUTICS

**Northwest Biotherapeutics is honored to be a
part of the British Neuro-Oncology Society
Annual Meeting 2026
and invites you to visit our stand and our
website for further information about our
DCVax® Personalized Immune Therapies
www.nwbio.com**



Message from the BNOS President



Professor Andrew Brodbelt
BNOS President

I would like to personally welcome you to Birmingham. The local team has put together a fantastic programme designed for everyone from the diverse community of The British Neuro-Oncology Society. Whilst we represent many different fields, we are all here for the same crucial reason: to improve patient's lives and ultimately cure brain tumours. The programme reflects that shared mission and shines a light on some of the people working hard to make it a reality. From basic science to clinical trials, improved treatments and pathways, every piece of the puzzle matters. I would like to encourage you to step outside your comfort zone – strike up a conversation with someone you don't know from a completely different area. Finally, for a different kind of challenge, we still have spaces available for our fun run. I truly hope you enjoy this event.



Key Information

Event Date

1st, 2nd & 3rd July 2026

Venue

Aston Webb Great Hall
University of Birmingham
Edgbaston
Birmingham
B15 2TT

Use what2words for accurate location: [The University of Birmingham, B15 2TT](#)

Registration

Please do not arrive before these times as we will be unable to allow access until registration is officially open.

There will be a trade exhibition and refreshments served on arrival, please make sure you visit our sponsors and abstracts.

Wednesday 1st July: 9:00–10:00

Thursday 2nd July: 8:00 – 9:00

Friday 3rd July: 8:15 – 9:00

Gala Dinner

The conference dinner is being held at The Council House, Victoria Square, Birmingham, B1 1BB on Thursday 2nd July from 19:30. Please note this is a ticketed event.

Networking & Poster Reception

Join us for the Welcome Networking & Poster Reception, held in the Aston Webb Great Hall, The University of Birmingham from 17:30. An ideal opportunity to connect with colleagues in a relaxed and inviting setting.

WIFI

Username- UoBGuestWiFi

Password- No password, you will need to sign up to access to WIFI.

App

Log in for full functionality. You will need the email you registered with and your individual App Pin (this will be in your final delegate email)

Edit your privacy and settings to allow delegates to view your details and connect.

Important: the default setting means delegates/exhibitors won't see your full name and details unless you allow access.

Please note the app will be open until 12pm on Friday 17th July, in this time you will be able to export your event notes and any connections you have made through the meeting hub.



Sponsored Symposiums

We are delighted to announce that our Platinum and Gold Sponsors will be hosting sponsored symposiums throughout the conference. Explore the sessions below to learn from industry leaders and gain valuable insights.

Don't miss these exclusive opportunities!

PLATINUM SPONSORS

Novocure



17:03–17:33 on Wednesday 1st July in The Elgar Concert Hall

Title: TTFields Therapy in Focus: Biology, Clinical Evidence, and UK Experience

Speakers: Dr. Waleed Mohammed, Consultant Clinical Oncologist

Charing Cross Hospital, London

Dr. Anup Vinayan, Consultant Clinical Oncologist, Mount Vernon Cancer Centre, London

Agenda

Welcome and introduction

Dr. Waleed Mohammed

• **TTFields in Glioblastoma:** Biology and Clinical Evidence

• **TTFields in Clinical Development**

Dr. Anup Vinayan

• **TTFields with Immunotherapy:** The KEYNOTE-D58 trial

• **TTFields in the UK:** TTFields in the UK: Real-World Experience in WHO Grade 4 Glioma

Discussion and close

Servier



11:38–12:08 on Thursday 2nd July in The Elgar Concert Hall.

Title: Patient Selection & MDT Decision-Making in mIDH Low Grade Glioma

Speakers: Liam Welsh, Clinical Oncologist, Royal Marsden

Northwest Biotherapeutics



NORTHWEST
BIOTHERAPEUTICS

10:03–10:33 on Friday 3rd July in The Elgar Concert Hall.

Title: DCVax-L -associated survival extension assessed through propensity score matching analyses

Speakers: Dr. Marnix Bosch, Chief Technical Officer, Northwest Biotherapeutics

GOLD SPONSOR

Brainlab



15:30–15:45 on Thursday 2nd July in the Aston Webb C Block.

Title: A users experience of Brainlab planning and mixed reality

Speakers: Osama Elmoursi, University of Birmingham and Vassili Crispi, University of Birmingham



Optune Gio[®] for newly diagnosed WHO grade 4 gliomas



Optune Gio has shown to provide long-term quality survival to patients with newly diagnosed WHO grade 4 gliomas¹

Mild-to-moderate skin irritation, the most common device-related adverse event, was observed in 52% of patients, and severe (grade 3) skin reaction in 2%. No increase in severe systemic AEs with Optune Gio¹

Optune Gio is a Class IIb CE Marked Medical Device (CE-0197). For more information on the intended purpose, contraindications and other safety information, please see the User Manual at: <https://manuals.novocure.eu/>

1. Stupp R, Taillibert S, Kanner A, et al. JAMA. 2017;318(23):2306-2316

* This was the secondary endpoint of the EF-14 Study. The primary Endpoint was PFS.

novocure[®]

novocure.co.uk



GALA DINNER

THURSDAY 2ND JULY

The Council House, Victoria Square, Birmingham, B1 1BB

We kindly ask all dinner guests to make their own way to the Council House for 7:20PM. Please note that this is a pre-booked event.

If you have any dietary requirements, please collect your dietary card from a member of the event team upon arrival.

Dress code: Smart casual attire

Arrival & Drinks
Reception
19:30



Call for dinner
19:50

Dinner Service
20:00-21:30



Entertainment
21:30-23:30



STARTER

Spiced chickpea soup served with a naan roll

MAIN

Black garlic chicken breast served with fondant potato, asparagus and peas with a white wine demi-glace (No alcohol)

or

Aubergine butter katsu, served with cumin and green pea rice and Bengali carrot salad (please note, this will only be provided if selecting vegetarian/vegan as a dietary requirement)

DESSERT

Chocolate torte and berries served with lotus powder and cinder toffee

TEA & COFFEE

Wednesday 1st July 2026

Main Plenary Sessions – The Elgar Concert Hall		Location Speaker
9:00 – 10:00	Registration, refreshments and exhibition	Aston Webb Great Hall
10:00 – 12:00	Session 1: Educational session: Rapid and ultra-rapid testing of brain tumours to meet patient clinical need	Chairs: Mr Stuart Smith & Dr Ute Pohl
10:00–10:14	Impact of waiting for a post operative diagnosis of brain tumour: The lived experience	Shalina Chowhan
10:15–10:20	Free Paper 42: The case for rapid molecular diagnosis; The power of PPIE	Dr Simon Newman
10:21–10:29	Top Scoring Abstract 17: Psychological and holistic consequences of delays in molecular diagnosis after neuro-oncological surgery: a qualitative study	Mr Jay Kotecha
10:29–10:35	Q&A	
10:35–10:50	Invited Speaker: Validation of the single shared genomic platform across early adopter sites	Prof Matt Loose
10:51–10:56	Free Paper 50: Comparative evaluation of long- and short-read methylation-aware sequencing for CNS tumour diagnostics	Dr Simon Deacon
10:57–11:02	Free Paper 101: Independent replication and validation of nanopore-based long read sequencing and methylome classification for rapid brain tumour diagnosis	Mr Vassili Crispi
11:02–11:13	Q&A	
11:14–11:29	Invited Speaker: Integrating rapid diagnostic sequencing into the paediatric neuro-oncology workflow	Prof Thomas Jacques
11:30–11:35	Free Paper 172: Transforming the National Genomic Test Directory to Improve Genomic Testing for CNS Tumours	Dr Jane Starczynski
11:36–11:46	Operational delivery of a networked local genomic platform within the NHS	Ms Victoria Wykes
11:46–12:00	Q&A / Debate	
12:00 – 13:00	Lunch and exhibition	Aston Webb Great Hall
12:30 – 13:00	Exhibitor Demos: BrainLab – Demonstration of Brainlab’s radio- and image guided surgery solutions	Exhibitor stands, Aston Webb Great Hall
13:00 – 13:05	Welcome to BNOS 2026	Ms Victoria Wykes
13:05 – 14:04	Plenary Session 1: Advancing Neuro-Oncology Trials and Research Innovation	Chairs: Ms Victoria Wykes & Dr Helen Benghiat
13:05 – 13:25	Keynote Speaker: Window trials to improve drug development in Glioma	Prof Nader Sanai
13:25–13:45	Invited Speaker: The need for Neuro-oncology Research Networks	Prof Colin Watts
13:46–13:54	EPIC-GB: an adaptive platform for window trials and translational science	Mr Ola Rominiyi
13:55–14:04	Access to Clinical Trials for Brain Tumours (ACT-BT)	Prof Susan Short
14:05–15:00	Town Hall Trials Landscape Update	Chairs: Prof Susan Short, Dr Sara Meade & Dr Elwira Szychot
14:05–14:10	ACTION – Onc 201 / placebo for Diffuse Midline Glioma	Prof Catherine McBain
14:10–14:15	VIGOR- Adjuvant Vorsasidenib following RT and adjuvant chemo for grade 2 and grade 3 astrocytomas	Prof Catherine McBain
14:16–14:21	Portrait (PreOpeRaTive pRerAdlotherapy TTFields)	Dr Gerben Borst
14:22 – 14:27	COMBAT-GB: COMBinATion Nivolumab and ASTX727 (decitabine and cedazuridine) for treatment of primary Glioblastoma	Prof Puneet Plaha
14:27 – 14:32	Recurrent-GB: Repeat ExCision Upon Recurrence: REthinking Neurosurgical Treatment of Glioblastoma	Prof Puneet Plaha
14:33 – 14:38	Approach-photons vs PBT for Grade 2 & 3 Oligodendrogliomas	Dr James Powell
14:39 – 14:49	Paediatric Medulloblastoma trials including MB6	Dr Jenny Adamski

*This programme is subject to ongoing changes

Wednesday 1st July 2026– Parallel Sessions



Parallel Sessions – Aston Webb C Block Lecture Theatre		Location Speaker
9:00 – 10:00	Registration, refreshments and exhibition	Aston Webb Great Hall
10:00 – 11:25	Education Session 2: Allied Health Professional Perspectives	Location & Speaker
10:00–10:05	Welcome	Will Garratt & Shivani Soni
10:05 – 10:55	Management of Low Grade Glioma	Chairs: Will Garratt & Shivani Soni
10:05–10:15	Long term health outcomes in oligodendrogliomas	Dr Florian Boele <i>Virtual</i>
10:16–10:26	Integrated Low Grade Glioma Care	Miss Kelly Dawson
10:27–10:37	A dedicated low grade glioma clinic: a holistic, patient centred approach	Mrs Charlotte Robinson
10:37–10:42	Free Paper 59: Early psychosocial support after a brain tumour diagnosis: a collaborative model between Southmead Hospital and Brain Tumour Support	Dr Lucy Wilkinson
10:42–10:55	Q&A + Discussion	
11:00 – 12:00	Prehabilitation	Chairs: Dr Diba Shariat, Georgie Harrington & Rosie Hawker
11:00–11:05	Free Paper 54: Access to Prehabilitation in UK Neuro-Oncology: Insights from a UK-wide review of adult brain tumour services (2024–2026)	Ms Sara Melhuish
11:06–11:11	Free Paper 89: Referral Patterns, Interventions and Outcomes: A 12 month Retrospective Review of Allied Health Professional Referrals from a Late Effects Clinic.	Mrs Paula Shukla
11:12–11:22	AHP service: Improving Patient Experience	Mr Gary Walsh & Miss Anne Jammes
11:23–11:33	Pathways to Prehab: A Neuro-Oncology Integration project.	Ms Kim Grove & Charlotte Britton
11:34–11:44	Prehabilitation in Cardiff	Mrs Cathryn Lewis
11:44–12:00	Q&A & Discussion	
12:00 – 13:00	Lunch and exhibition	Aston Webb Great Hall

Wednesday 1st July 2026 (Continued)

Main Plenary Sessions – The Elgar Concert Hall		Location Speaker
14:50 – 14:55	CARE study: Phase 2 open-label study: Repotrectinib in paediatric and young adult patients with advanced or metastatic malignancies harbouring ALK, ROS1 or NTRK1-3 alterations.	Dr Elwira Szychoł
14:55– 15:00	EORTC Update	Prof Susan Short
15:00–15:30	Refreshments and exhibitor	Aston Webb Great Hall
15:00 – 15:30	Exhibitor Demos: myTomorrows – How Sites Receive Qualified Referrals: See how AI matching and patient navigation reduce screening burden and support site recruitment workflows	Exhibitor stands, Aston Webb Great Hall
15:30–17:30	Session 2: Glioma: Optimising Radiotherapies	Chairs: Dr Paul Sanghera & Mr Thanos Zisakis
15:30–15:55	Keynote Speaker: Improving tumour control and reducing neurotoxicity by combining radiotherapy with inhibitors of the DNA damage response	Prof Anthony Chalmers
15:55–16:15	Invited Speaker: Investigating targeted radiotherapies for the effective treatment of glioblastoma	Prof Jason Parsons
16:15–16:25	Top Scoring Abstract 156: Multidisciplinary decision-making in the management of recurrent glioblastoma – a multi-centre UK questionnaire study.	Mr Chris McKinnon
16:26–16:33	Free Paper 31: CD44–Gal9 Interaction between IDH1–mutant Grade 4 Astrocytoma and Microglia Promotes Invasion and Proliferation of Tumor Cells	Ms Nathalie Große
16:34–16:41	Free Paper 117: Transcript-resolved mapping of the m6A RNA modification landscape in glioma using nanopore direct RNA sequencing	Dr Simon Deacon
16:42–16:49	Free Paper 136: Tessa Jowell BRAIN MATRIX interim analysis: surgical and oncology outcomes in glioblastoma patients	Mr Vassili Crispi
16:50–16:57	Free Paper 122: Surgical Outcomes for High Grade Glioma in Patients Aged 70 Years and Older: A 10 Year Single Centre Cohort Study	Mr Hazem Eid
16:58 – 17:03	Power Pitch 68: Adjuvant chemotherapy in WHO Grade 2 Astrocytoma: Retrospective Analysis at NNUH to Inform a Multicentre Comparative Study	Dr Rebecca Brooks
17:03 – 17:33	Platinum Sponsored talk: TTFIELDS Therapy in Focus: Biology, Clinical Evidence, and UK Experience	Novocure: Dr Waleed Mohammed & Dr Anup Vinayan
17:33	Close of session	
17:30 – 18:00	BNOS Mentor and Mentee meet up	Aston Webb Hall
17:30 – 19:00	Networking & Poster Reception	Aston Webb Great Hall, University of Birmingham
17:30 – 19:00	The Birmingham Boron Neutron Capture Therapy Facility timed visits	Meet outside reception of Aston Webb Great Hall
18:10–18:51	Power Pitch Session	Lecture Theatre G33 Chairs: Dr Ute Pohl & Dr Katherine Eales
18:10–18:15	148: Using real-world data from GlioCova to assess the feasibility and revise the design of the ARISTOCRAT trial in recurrent glioblastoma	Dr Josh Savage
18:16–18:21	165: Astrocyte–Glioblastoma Metabolic Interactions at the Invasive Margin Reveal Therapeutic Vulnerabilities	Ms Une Kontrimaite
18:22–18:27	58: Disrupting metabolic plasticity in glioblastoma stem-like cells via FABP7 inhibition and DHA supplementation	Ms Cécilia Bernier
18:34–18:39	98: Barriers and opportunities in the integrated histopathological-molecular diagnosis of adult diffuse gliomas: a national survey of neuropathology units in UK&I	Mr Vassili Crispi
18:40–18:45	74: Development and evaluation of a personalised prognostic prediction model for overall survival in patients with glioblastoma using machine-learning methods.	Miss Alina Morozova
18:46–18:51	55: Radiotherapy Peer Review in Neuro-Oncology: National Survey of Practice, Barriers and AI Integration	Dr Sarah Kingdon

Wednesday 1st July 2026– Parallel Sessions (Continued)

Parallel Sessions – Aston Webb C Block Lecture Theatre		Location Speaker
15:00–15:30	Refreshments and exhibiton	Aston Webb Great Hall
15:30–16:50	Parallel Session 2: AHP: Survivorship and quality of life	Chairs: Claire Goddard, Shivani Soni & Rhona Watson
15:30–15:35	Free paper 57: The role of the Clinical Nurse Specialist in neuro-oncology: Insights from a UK-wide review of adult brain tumour services (2020–2026)	Mrs Jillian Sokratous
15:36–15:41	Free paper 22: Quality of life and services use in patients diagnosed with brain tumours: data from a national cancer survivorship study	Ms Kerlann Le Calvez
15:42–15:47	Free paper 15: Promoting the need for a dedicated Neuro-Oncology Occupational Therapy Service at QEHB: A Quality Improvement Project	Miss Megan Jones
15:48–15:53	Free Paper 37: Outcomes of a National Specialist Counselling Service for People Affected by Brain Tumours	Ms Joanna Moss
15:54–15:59	Free Paper 90: Developing Patient-Focused Outcomes for Routine Clinical Care in Glioma: A Synthesis of Qualitative Evidence from the COMBaT Study.	Dr Noreen Hopewell-Kelly
16:00–16:05	Free Paper 167: Improving safe delivery of steroids and side effect management in brain tumour patients.	Dr Louise Dulley
16:05–16:15	Q&A	
16:15–16:55	AHP Career Development workshop	Chairs: Shivani Soni & Rhona Watson & Mitchell Hickman
16:15–16:35	Developing Your Research Career: TJBCM Opportunities and Insights from the AHP Research Fellowship Programme	TJBCM Camille Goetz
16:35–16:45	Understanding the benefits, key components and delivery considerations of prehabilitation for adults with high grade primary brain tumour in the UK	TJBCM Alice Franklin <i>Virtual</i>
16:45–16:55	Q&A	
17:30	Close of session	
17:30 – 18:00	BNOS Mentor and Mentee meet up	Aston Webb Great Hall
17:30 – 19:00	Networking & Poster Reception	Aston Webb Great Hall, University of Birmingham
17:30 – 19:00	The Birmingham Boron Neutron Capture Therapy Facility timed visits	Meet outside reception of Aston Webb Great Hall

Main Plenary Sessions – The Elgar Concert Hall		Location Speaker
7:00	BNOS 5K Run	Meet at Leonardo Hotel
8:00–09:00	Registration, refreshments and exhibition	Aston Webb Great Hall
09:00–10:30	Session 3: Preclinical models of brain tumour	Chairs: Dr Phoebe McCrorie, Mr Stuart Smith & Dr Katherine Eales
9:00 – 9:20	Keynote speaker: Predictive patient-derived glioma organoid models for functional precision neuro-oncology	Prof Haikun Liu
9:20–9:35	Invited Speaker: Design and development of Chemoseed for local brain tumour drug delivery	Prof Chris McConville
9:35–9:50	Invited Speaker: From single-cell omics to patient derived cells: dissecting and modeling glioblastoma heterogeneity	Prof Sara Piccirillo
9:50–10:00	Q&A and discussion	
10:00–10:30	Abstracts Laboratory, translational and clinical science	
10:00–10:10	Top scoring abstract 41: Pharmacological depletion of NAD ⁺ has single agent cytotoxicity and radiosensitises glioma stem-like cells through impaired DNA replication and repair.	Prof Anthony Chalmers
10:11–10:18	Free paper 129: Electroactive drug delivery for local glioblastoma treatment	Mr Joshua Killilea
10:19–10:26	Free Paper 5: A multivariate plasma biomarker model enabling safe exclusion of glioblastoma	Mr Jonathan Decarpentrie
10:30 – 11:00	Refreshments and exhibiton	Aston Webb Great Hall
11:00–11:38	Updates in Vorasidenib	Chair : Prof Andrew Brodbelt & Dr Paul Sanghera
11:00–11:15	Free paper 137 & 138: Phase 3 INDIGO trial of vorasidenib versus placebo: updated efficacy, safety and exploratory analysis of seizures and quality of life	Prof Catherine McBain
11:15–11:22	Free paper 35: Access to Vorasidenib for Low-Grade Glioma in the UK: Voices of Patients, Carers and Clinicians	Miss Shannon Winslade
11:23–11:30	Free Paper 102: Real-world Use of Vorasidenib in Adult IDH1/2-Mutant Low-Grade Glioma Across UK NHS Trusts	Mr Abraham Sondhi
11:31–11:38	Free paper 145: Implementing Vorasidenib in Clinical Practice: A Single-Centre Real-World Service Evaluation	Dr Brooke Smart
11:38–12:08	Platinum Sponsored Talk: Patient Selection & MDT Decision-Making in mIDH Low Grade Glioma	Servier, Prof Liam Welsh, Clinical Oncologist, Royal Marsden
12:09–12:20	Young Investigator Award sponsored by BTR and BNOS	 
12:20–12:30	BNOS Conference photo	
12:30 – 13:30	Lunch and exhibition	Aston Webb Great Hall
13:00 – 13:30	Exhibitor demos: Novocure – An introduction to TTFields	Aston Webb Great Hall
13:30–15:00	Plenary Session 3: Mapping Neuro-oncology to National Strategy	Chair: Prof Colin Watts
13:30 – 13:50	Keynote Speaker: Overview of the National Cancer plan	Mr David Fitzgerald
13:50 – 14:05	Invited Speaker: Analogue to digital implications for clinical trials	Prof Amos Burke
14:05 – 14:20	Invited Speaker: From hospital to community the West Midlands Perspective	Dr Sonia Ashraf
14:20–14:35	Invited Speaker: National Strategies- turning promise into practice	Mr Cameron Miller
14:35–15:00	Panel discussion	

Thursday 2nd July 2026– Parallel Sessions



Parallel Sessions – Aston Webb C Block Lecture Theatre		Location Speaker
7:00	BNOS 5K Run	
8:00–9:00	Registration, refreshments and exhibition	Aston Webb Great Hall
09:00–10:30	Session 3: Parallel Session Paediatric and TYA	Chairs: Dr Helen Benghiat, Dr Elwira Szychot, Dr John Apps & Mr Will Lo
09:00–09:25	Keynote speaker: Updates on CNS germinoma: the MonoGerm trial and utility of CSF miR-371a-3p	Prof Matthew Murray
09:26–09:36	Top Scoring Abstract 109: Multi-omic integration reveals intra-tumour heterogeneity and identifies disulfiram and copper as a synergistic therapy in paediatric ependymoma	Dr. Alina Pandele
09:37–09:44	Free Paper 142: Arginine deprivation improves survival and activates the immune system in mouse models of diffuse midline glioma.	Ms Molly Brooks
09:45–09:52	Free Paper 152: Re-irradiation for recurrent paediatric diffuse midline glioma: an international, multi-institutional retrospective study.	Dr Helen Benghiat
09:53–10:00	Free Paper 11: Single-nucleus and spatially resolved multi-omics uncover intracranial germinomas' microenvironment and associated molecular features	Professor Ho-Keung Ng
10:01–10:08	Free Paper 103: A Medulloblastoma brain slice culture radiotherapy platform to dually assess therapeutic efficacy and toxic	Miss Kristy Kehoe
10:09–10:16	Free Paper 119: Developing a Teenage and Young Adult Brain Tumour Standard Operating Procedure in a UK Tertiary Neurosciences Centre	Miss Aimee Goel
10:17–10:22	Power Pitch 118: Molecular and Immunological Landscape of the Pleomorphic Xanthoastrocytoma–Epithelioid Glioblastoma Spectrum	Dr. Iman Dandapath
10:23–10:30	Free Paper 147: Cutting the power: targeting what fuels aggressive brain cancer	Dr Katherine Eales
10:30 – 11:00	Refreshments and exhibitor	Aston Webb Great Hall
No parallel sessions at this time		
12:30 – 13:30	Lunch and exhibition	Aston Webb Great Hall
No parallel sessions at this time		
15:00 – 15:30	Refreshments and exhibitor	Aston Webb Great Hall
15:30–17:30	Parallel Session 4: Imaging	Chair: Dr Harpreet Hyare and Prof Vijay Sawlani
15:30–15:45	Gold sponsor talk: A users experience of Brainlab planning and mixed reality	Brainlab: Mr Osama Elmoursi & Mr Vassili Crispi

Thursday 2nd July 2026 (Continued)

Main Plenary Sessions – The Elgar Concert Hall		Location
		Speaker
15:00 – 15:30	Refreshments and exhibitor	Aston Webb Great Hall
15:30–17:30	Session 4: Metastasis and other CNS tumours	Dr Vinton Cheng, Dr Mihaela Lorgier & Mr Rasheed Zakaria
15:30 – 15:50	Keynote Speaker: Cancer Neuroscience of Brain Metastases	Dr Matthia Karreman
15:50–16:10	Invited Speaker: Leptomeningeal metastasis: translational research and future directions	Dr Amanda Fitzpatrick
16:10–16:25	Debate/ Q&A	
16:26–16:36	Top Scoring Abstract 46: Anti-tumour immune responses in melanoma brain metastases require cDC1 population and the extracranial tumour	Dr Dario Guglietta
16:37–16:44	Free Paper 76: Metabolic heterogeneity in Brain Tumours: Distinguishing brain metastases from glioblastomas	Ms Ishana Rajgopal
16:45–16:52	Free Paper 94: Outcome of patients with metastatic lung cancer presenting with synchronous brain metastases – A single centre; 5 year retrospective analysis.	Dr Harriet Hebbes
16:53–17:00	Free paper 82: Proton versus photon stereotactic radiotherapy for brain metastases unsuitable for single-fraction stereotactic radiosurgery: a dosimetric comparison with robustness analysis	Dr Vanita Gandhi
17:01–17:08	Free Paper 77: Outcomes Following Stereotactic Radiosurgery for Brain Metastases from Lung Adenocarcinoma: The Wessex Experience	Dr Arda Karakaya
17:09–17:16	Free Paper 9: Development of a Rapid Lateral Flow Assay for Early Identification of Glioblastoma and Brain Metastases Using a Circulating Serum Biomarker	Ms Carys Jordan
17:17–17:24	Free Paper 21: Adult ependymoma in England: Incidence, treatment, and outcomes from GlioCova	Ms Kerlann Le Calvez
17:30	Close of session	
17:30–18:00	BNOS AGM	Elgar Concert Hall
19:30 – 23:00	Gala Dinner	Council House, Birmingham

Thursday 2nd July 2026– Parallel Sessions (Continued)

Parallel Sessions – Aston Webb C Block Lecture Theatre		Location Speaker
15:30–17:30	Parallel Session 4: Imaging (continued)	Chair: Dr Harpreet Hyare and Prof Vijay Sawlani
15:46– 16:11	Invited Speaker: AI RANO	Dr Thomas Booth
16:11 – 16:26	Predicting sites of tumour progression in the invasive margin of glioblastomas (PRaM-GBM Study): a multicentre imaging study	Prof Stephen Price
16:27 – 16:37	Top Scoring abstract 24: Human-AI collaboration in brain tumour assessments improves both human and AI agent performance	Dr James Ruffle
16:38 – 16:45	Free paper 88: Slip Interface Imaging in Glioblastoma: A Pilot Study of Tumour-Brain Adhesion and Surgical Resectability	Dr Lucy Hiscox
16:46 – 16:53	Free Paper 80: The Multi-Modal Combination of Magnetic Resonance Spectroscopy and Apparent Diffusion Coefficient Features Improves Radiological Prognostic Stratification of Paediatric Medulloblastoma	Mr Timothy Mulvany
16:54 – 17:01	Free Paper 60: Persistent minimal contrast enhancement following autologous stem cell transplantation in primary CNS lymphoma	Miss Ellie-May Bond
17:02 – 17:07	Power Pitch 108: Interpretable Radiomics-Based Prediction of IDH Status in Glioma	Dr James Powell
17:08 – 17:13	Power Pitch 120: Updates on Magnetic Resonance Imaging assessment of tumour MicroStructure in Glioblastoma: A cross-sectional study (The MIMOSA Study)	Dr Jennifer Golten
17:14 – 17:19	Power Pitch 56: The evolving challenges and opportunities in adult brain tumour imaging: Insights from a review of United Kingdom neuro-oncology centres (2021–2024)	Prof Adam Waldman
17:30	Close of session	
19:30 – 23:00	Gala Dinner	Council House, Birmingham

Main Plenary Sessions – The Elgar Concert Hall		Location Speaker
8:15–9:00	Registration, refreshments and exhibition	Aston Webb Great Hall
09:00–11:00	Session 5: Design and Delivery of Novel Therapies	Chairs: Dr Vinton Cheng & Ms Victoria Wykes
9:00 – 9:25	Keynote Lecture: Tailoring Therapy in Recurrent GBM Using Personalized Assay Platforms	Prof Soma Sengupta
9:25–9:45	Invited Speaker: An AAV-1 mediated dual-payload ADePT: an AAV-1 mediated dual payload gene therapy for high grade glioma	Dr Faye Robertson
09:45–10:00	Abstracts: Clinical trials and emerging treatments	
09:45–09:50	Power Pitch 18: TTFields with maintenance temozolomide/pembrolizumab versus TTFields with maintenance temozolomide/placebo for newly diagnosed glioblastoma: the phase 3 EF-41/KEYNOTE D58 trial	Dr Gerben Borst
09:51–09:56	Power Pitch 27: Development of Precision Virotherapies for Diffuse Midline Gliomas	Ms Mariana Varela Pereira
09:57–10:02	Power Pitch 150: The Value of Early Biological Information in Glioblastoma Drug Development: A Health Economic Evaluation of Window-of-Opportunity Trials	Dr Melyda Melyda
10:03–10:33	Platinum Sponsored talk: DCVax-L –associated survival extension assessed through propensity score matching analyses	Dr. Marnix Bosch, Chief Technical Officer, Northwest Biotherapeutics
10:30–11:00	Refreshments & Exhibition	Aston Webb Great Hall
10:30 – 11:00	Exhibitor demos: Inomed – SUSy stereotactic frame Oxford Nanopore Technologies	Exhibitor stands, Aston Webb Great Hall
11:00–12:45	Plenary Session 6: Neuro-oncology Future Strategy to address challenges	Chairs: Prof Andrew Brodbelt & Prof Stephen Price
11:00–11:25	Keynote lecture: NIHR Consortium	Prof Juanita Lopez
11:25–11:32	Free Paper 51: Does it matter where you are treated? Insights from a national review of NHS brain tumour services (2020–2026)	Dr Nicky Huskens
11:33–11:40	Free Paper 36: The cost of a brain tumour: The Economic Case for Urgent Action	Ms Clair Thorstensen-Woll
11:45–12:30	Neuro-Oncology Future Strategy Discussion	Prof Andrew Brodbelt Prof Stephen Price
12:30–12:35	BNOS 2027: Royal Surrey Hospital, Guildford On behalf of the St George's Hospital/ Royal Marsden/ Royal Surrey Tessa Jowell Centre of Excellence	Dr Mazhar Ajaz
12:35–12:45	Closing remarks	Prof Andrew Brodbelt
12:45 – 14:00	Departure lunch and exhibition	Aston Webb Great Hall

14:00 – 16:00	Student and trainee committee: Updates in Advanced Diagnostics and Therapeutics in Neuro-oncology	The Elgar Concert Hall Chairs: Miss Aimee Goel & Mr Vassili Crispi
14:00 – 14:30	Neuroradiology advances	Prof Vijay Sawlani and Dr Markand Patel
14:30 – 15:00	Neuropathology bootcamp	Dr Ute Pohl and Dr Simon Deacon
15:00 – 15:30	Radiotherapy Frontiers	Dr Sara Meade and Mr Timothy Jackson
15:30 – 16:00	Targeted therapies in Neurooncology	Dr Vinton Cheng and Ms Victoria Wykes
16:00 – 16:15	Rehabilitation and seizure management in Neurooncology	Dr Diba Shariat and Dr Smriti Bose

*This programme is subject to ongoing changes

Friday 3rd July 2026– Parallel Sessions



Parallel Sessions – Aston Webb C Block Lecture Theatre		Location Speaker
8:15 – 9:00	Registration, refreshments and exhibition	Aston Webb Great Hall
09:00–10:00	Parallel session 5: Global Neuro–Oncology	Chairs: Prof Andrew Brodbelt, Ms Saqiba Jadoon
9:00 – 9:25	Neuro–Oncology in Gaza	Mr Ismail Urgratdhar
9:26 – 9:36	Neuro–Oncology in Nepal	Dr Deependra Shrestha Simangainda BNOS Global Scholar
9:36 – 9:46	Neurosurgical Oncology in Ethiopia	Dr Salahadin Bedru Mohammed BNOS Global Scholar
09:47–09:57	Top scoring abstract 130: Delivering Global Skull Base Education By WhatsApp – Experience From The January 2025 Vestibular Schwannoma Challenge.	Dr Dilaxiha Rajendran
No parallel sessions at this time		
10:30–11:00	Refreshments & Exhibition	Aston Webb Great Hall
No parallel sessions at this time		
12:45	Departure lunch and exhibition	Aston Webb Great Hall
13:00–14:30	BNOS Council Meeting	Aston Webb C Block Lecture Theatre

All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers (unless declared on the programme) and have provided sponsorship monies used towards the meeting costs. Sponsors will have the opportunity to exhibit with a company stand during the meeting.

Ultrasound Navigation

Dynamic Layer of Confidence

Experience a whole new dimension. In real time. At anytime. We're redelivering innovative, science-backed technology to help surgeons achieve their goal of maximum safe resection, even if brain shift or other navigational inaccuracies occur. We're operationalizing ultrasound navigation in a new way, transforming this intraoperative imaging technology to deliver a dynamic layer of confidence.





With thanks from our sponsors

Platinum Sponsors



NORTHWEST
BIOTHERAPEUTICS

novocure®

SERVIER

Gold Sponsor

 BRAINLAB

Silver Sponsors

 Jazz Pharmaceuticals. **inomed**  :medac pharma

my**tomorrows**

 Oxford
Nanopore
Technologies

Bronze Sponsors

lemonchase
DESIGNS FOR VISION

THE
BRAIN
TUMOUR
CHARITY

 Data4NHS
Data providers to the NHS

 GE HealthCare

INTEGRA 

stryker

Medtronic

ZEISS

Charity Bronze Sponsors

Tessa Jowell
BRAIN CANCER MISSION


Brain Tumour
Research

brainstrust
the brain cancer people

 willow
special days for seriously ill young adults

 BRAIN UK
Enabling research into
neurological disease

All sponsors have provided sponsorship towards this independent programme. Sponsors have had no input into the content of the programme or the choice of speakers (unless declared on the programme) and have provided sponsorship monies used towards the meeting costs. Sponsors will have the opportunity to exhibit with a company stand during the meeting.

Recruit smarter. Enroll faster.

We help clinical research teams identify and enroll relevant patients faster by combining AI-powered matching, patient navigation and high-quality referrals, reducing site burden and accelerating enrollment.

26%

Reduction in
screen failure rate

58%

Less time
managing referrals

43%

Increase in qualified
patient referrals

98%

AI pre-screening
accuracy



Unified platform

One platform for patient referral management, AI matching, analytics, and trial-ready patient workflows.



Continuous matching

Identify potentially eligible patients across site populations, EHRs, referral networks and active studies with our matching API integration.




Structured referrals

Dedicated patient navigators support patients throughout their journey and only send highly qualified referrals.

[REQUEST A DEMO](#)

medical-community@mytomorrows.com



FUNCTIONAL NEUROSURGERY

Single-use biopsy probes



With Sedan side-cutting window

Reveal more biology to transform human health

Advance your understanding
of health and disease

Oxford Nanopore has developed a new generation of DNA/RNA sequencing technology. It uniquely delivers real-time analysis, scales from pocket-sized devices to population-level studies, and sequences any length of native DNA or RNA — capturing all the insights you need, in one go.

Our technology is used across diverse research areas, from human genomics and cancer research to microbiology, plant science, and environmental studies.

The global research community has shown that Oxford Nanopore sequencing can access regions of the genome beyond the reach of legacy short-read technologies — providing more comprehensive genomic analysis and advancing our understanding of health and disease.



[oxford-nanopore-technologies](#)

[@nanoporetech](#)

[@nanoporetech.com](#)

Oxford Nanopore Technologies, the Wheel icon, and PromethION are registered trademarks or the subject of trademark applications of Oxford Nanopore Technologies plc in various countries. Information contained herein may be protected by copyright, patents or patents pending of Oxford Nanopore Technologies plc. © 2026 Oxford Nanopore Technologies plc. All rights reserved. Oxford Nanopore Technologies products are RUO. Products labelled/branded as Oxford Nanopore Diagnostics may be RUO or may be regulated as in-vitro diagnostic devices in some jurisdictions, please check individual product labelling.

Become a Member of BNOS!



BNOS brings together professionals from across clinical and scientific disciplines involved in the treatment, management and research of CNS tumours in both children and adults.

Membership is also open to individuals from charities and non-profit organisations working in neuro-oncology research or those supporting patients and carers. For individuals active in Patient and Public Involvement (PPI) but without current employment/income we offer waived membership fees.

What BNOS membership provides:

Members gain access to a broad set of benefits, including:

- BNOS Members' Area with resources, lecture recordings, and webinars
- Discounted registration for the annual BNOS conference
- Eligibility for bursaries (for reduced-rate members)
- Exclusive member-only events and programmes
- Discounts on article processing charges for selected journals via MDPI affiliation
- Discounts on selected third-party training courses
- Networking across neuro-oncology disciplines
- AGM attendance and voting rights

Find out more and join us by scanning the QR code or visiting the members page on the app.



This image shows a blank sheet of white paper with horizontal black ruling lines. The lines are evenly spaced and run across the width of the page, providing a template for writing or drawing. There are no margins, text, or other markings on the paper.

[illegible]

On behalf of BNOS, thank you for attending the 2026 Annual Meeting at The University of Birmingham.

We were delighted to welcome colleagues from across the neuro-oncology community for an engaging and successful meeting. Your participation and contributions helped create valuable discussions, foster new collaborations, and make the event a memorable experience for all involved.

We hope you found the programme informative, inspiring, and enjoyable, and we thank you for your continued support of BNOS.

We look forward to welcoming you to BNOS 2027!

The British Neuro-Oncology Society's New
Professional Conference Organising Team

Website:

<https://www.eventmanagementdirect.co.uk>



Providing Excellence in Event Management

